Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice

Toxicology and Applied Pharmacology

Volumn 272, Issue 3, 2013, Pages 816-824

  Liu, Jie ^a,b   Lu, Yuan Fu ^a,b   Zhang, Youcai ^a   Wu, Kai Connie ^a   Fan, Fang ^a   Klaassen, Curtis D ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Bile acid synthesis genes; Bile acid transporters; Cholestasis; Nuclear receptors; Oleanolic acid; Serum bile acids

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILE ACID CONJUGATE; BILIRUBIN; CARRIER PROTEIN; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME; CYTOCHROME P450 1A2; CYTOCHROME P450 3A11; CYTOCHROME P450 4A10; CYTOCHROME P450 CYP8B1; NTCP PROTEIN; OATP1B2 PROTEIN; OLEANOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; BILE ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID METABOLISM; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; FEMALE; INTRAHEPATIC CHOLESTASIS; LIVER HISTOLOGY; LIVER TOXICITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHOLESTASIS; DOSE RESPONSE; METABOLISM; TOXIC HEPATITIS; TOXICITY;

MUS;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; MICE; MICE, INBRED C57BL; OLEANOLIC ACID;

EID: 84884725177     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.08.003     Document Type: Article

References (49)

1. Ballatori N., Li N., Fang F., Boyer J.L., Christian W.V., Hammond C. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front. Biosci. 2009, 14:2829-2844.
2. Bilgi N., Bell K., Ananthakrishnan A.N., Atallah E. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann. Pharmacother. 2010, 44:926-928.
3. Boyer J.L., Trauner M., Mennone A., Soroka C.J., Cai S.Y., Moustafa T., Zollner G., Lee J.Y., Ballatori N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G1124-G1130.
4. Cheng X., Buckley D., Klaassen C.D. Regulation of hepatic bile acid transporters Ntcp and Bsep expression. Biochem. Pharmacol. 2007, 74:1665-1676.
5. Chiang J.Y. Bile acids: regulation of synthesis. J. Lipid Res. 2009, 50:1955-1966.
6. Chitturi S., Farrell G.C. Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol. 2008, 23:366-373.
7. Copple B.L., Jaeschke H., Klaassen C.D. Oxidative stress and the pathogenesis of cholestasis. Semin. Liver Dis. 2010, 30:195-204.
8. Csanaky I.L., Lu H., Zhang Y., Ogura K., Choudhuri S., Klaassen C.D. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. Hepatology 2011, 53:272-281.
9. Fiorucci S., Zampella A., Distrutti E. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr. Top. Med. Chem. 2012, 12:605-624.
10. Guinda A., Rada M., Delgado T., Gutiérrez-Adánez P., Castellano J.M. Pentacyclic triterpenoids from olive fruit and leaf. J. Agric. Food Chem. 2010, 58:9685-9691.
11. Kinjo J., Okawa M., Udayama M., Sohno Y., Hirakawa T., Shii Y., Nohara T. Hepatoprotective and hepatotoxic actions of oleanolic acid-type triterpenoidal glucuronides on rat primary hepatocyte cultures. Chem. Pharm. Bull. 1999, 47:290-292.
12. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 2010, 62:1-96.
13. Laszczyk M.N. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009, 75:1549-1560.
14. Li M.K., Crawford J.M. The pathology of cholestasis. Semin. Liver Dis. 2004, 24:21-42.
15. Li N., Xia Q., Ruan J., Fu P.P., Lin G. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. Curr. Drug Metab. 2011, 12:823-834.
16. Licata A., Macaluso F.S., Craxì A. Herbal hepatotoxicity: a hidden epidemic. Intern. Emerg. Med. 2013, 8:13-22.
17. Liu J. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49:57-68.
18. Liu J. Oleanolic acid and ursolic acid: research perspectives. J. Ethnopharmacol. 2005, 100:92-94.
19. Liu W., Wong C. Oleanolic acid is a selective farnesoid X receptor modulator. Phytother. Res. 2010, 24:369-373.
20. Liu J., Liu Y., Madhu C., Klaassen C.D. Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice. J. Pharmacol. Exp. Ther. 1993, 266:1607-1613.
21. Liu Y., Kreppel H., Liu J., Choudhuri S., Klaassen C.D. Oleanolic acid protects against cadmium hepatotoxicity by inducing metallothionein. J. Pharmacol. Exp. Ther. 1993, 266:400-406.
22. Liu J., Liu Y., Mao Q., Klaassen C.D. The effects of 10 triterpenoid compounds on experimental liver injury in mice. Fundam. Appl. Toxicol. 1994, 22:34-40.
23. Liu J., Liu Y., Klaassen C.D. Protective effect of oleanolic acid against chemical-induced acute necrotic liver injury in mice. Zhongguo Yao Li Xue Bao 1995, 16:97-102.
24. Liu J., Wu Q., Lu Y.F., Pi J. New insights into generalized hepatoprotective effects of oleanolic acid: key roles of metallothionein and Nrf2 induction. Biochem. Pharmacol. 2008, 76:922-928.
25. Lu H., Choudhuri S., Ogura K., Csanaky I.L., Lei X., Cheng X., Song P.Z., Klaassen C.D. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol. Sci. 2008, 103:35-45.
26. Lu Y.F., Wan X.L., Xu Y., Liu J. Repeated oral administration of oleanolic acid produces cholestatic liver injury in mice. Molecules 2013, 18:3060-3071.
27. Maher J.M., Aleksunes L.M., Dieter M.Z., Tanaka Y., Peters J.M., Manautou J.E., Klaassen C.D. Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol. Sci. 2008, 106:319-328.
28. Milkiewicz P., Heathcote J. Cholestasis induced by Chinese herbal remedy Xia-Ku-Hua-Tan-Pian. Liver Int. 2011, 31:746-747.
29. Okada K., Shoda J., Taguchi K., Maher J.M., Ishizaki K., Inoue Y., Ohtsuki M., Goto N., Sugimoto H., Utsunomiya H., et al. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem. Biophys. Res. Commun. 2010, 389:431-436.
30. Petronelli A., Pannitteri G., Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20:880-892.
31. Pollier J., Goossens A. Oleanolic acid. Phytochemistry 2012, 77:10-15.
32. Reisman S.A., Aleksunes L.M., Klaassen C.D. Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem. Pharmacol. 2009, 77:1273-1282.
33. Roth M., Araya J.J., Timmermann B.N., Hagenbuch B. Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J. Pharmacol. Exp. Ther. 2011, 339:624-632.
34. Saaby L., Jäger A.K., Moesby L., Hansen E.W., Christensen S.B. Isolation of immunomodulatory triterpene acids from a standardized rose hip powder (Rosa canina L.). Phytother. Res. 2011, 25:195-201.
35. Sato H., Genet C., Strehle A., Thomas C., Lobstein A., Wagner A., Mioskowski C., Auwerx J., Saladin R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 2007, 362:793-798.
36. Seeff L.B. Herbal hepatotoxicity. Clin. Liver Dis. 2007, 11:577-596.
37. Sharma S., Sharma O.P., Dawra R.K., Bhat T.K. Disposition of lantadene A, the pentacyclic triterpenoid hepatotoxin, orally administered to guinea pigs. Toxicol. Lett. 1999, 105:59-66.
38. Tanaka Y., Aleksunes L.M., Cui Y.J., Klaassen C.D. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol. Sci. 2009, 108:247-257.
39. Teschke R., Glass X., Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul. Toxicol. Pharmacol. 2011, 61:282-291.
40. Teschke R., Sarris J., Schweitzer I. Kava hepatotoxicity in traditional and modern use. The presumed Pacific kava paradox hypothesis revisited. Br. J. Clin. Pharmacol. 2012, 73:170-174.
41. Wagner M., Zollner G., Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 2010, 30:160-177.
42. Wang J.B., Zhao H.P., Zhao Y.L., Jin C., Liu D.J., Kong W.J., Fang F., Zhang L., Wang H.J., Xiao X.H. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS One 2011, 6:e24498.
43. Weerachayaphorn J., Mennone A., Soroka C.J., Harry K., Hagey L.R., Kensler T.W., Boyer J.L. Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G925-G936.
44. Wu K.C., Liu J.J., Klaassen C.D. Nrf2 activation prevents cadmium-induced acute liver injury. Toxicol. Appl. Pharmacol. 2012, 263:14-20.
45. Xi J., Tang H., Zheng Y. Oral dosage forms of oleanolic acid and their pharmacokinetics. Chin. J. New Drugs 2009, 18:507-515.
46. Zhang Y., Klaassen C.D. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J. Lipid Res. 2010, 51:3230-3240.
47. Zhang W., Popovich D.G. Chemical and biological characterization of oleanane triterpenoids from soy. Molecules 2009, 14:2959-2975.
48. Zhang Y., Hong J.Y., Rockwell C.E., Copple B.L., Jaeschke H., Klaassen C.D. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int. 2012, 32:58-69.
49. Zoja C., Corna D., Nava V., Locatelli M., Abbate M., Gaspari F., Carrara F., Sangalli F., Remuzzi G., Benigni A. Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Renal Physiol. 2013, 304:F808-F819.